RASSF1A regulation of transcription factors in tumourigenesis and stem cell fate determination

RASSF1A silencing is the most widely reported epigenetic event in sporadic human malignancies and is increasingly observed to be associated with poorer prognosis and outcome in lung, breast and bladder cancers amongst others. By performing a genetic screen in mice using Sleeping Beauty (SB) transpos...

Descrición completa

Detalles Bibliográficos
Autor Principal: Papaspyropoulos, A
Outros autores: O'Neill, E
Formato: Thesis
Idioma:English
Publicado: 2014
Subjects:
_version_ 1826310335491997696
author Papaspyropoulos, A
author2 O'Neill, E
author_facet O'Neill, E
Papaspyropoulos, A
author_sort Papaspyropoulos, A
collection OXFORD
description RASSF1A silencing is the most widely reported epigenetic event in sporadic human malignancies and is increasingly observed to be associated with poorer prognosis and outcome in lung, breast and bladder cancers amongst others. By performing a genetic screen in mice using Sleeping Beauty (SB) transposon-mediated insertional mutagenesis, we identified candidate genes associated with tumourigenesis in the absence of Rassf1a. A top hit in our screen was the terminal differentiation transcription factor Runx2. In this study, we describe how together loss of RASSF1A and RUNX2 exacerbate oncogenic YAP1-TEAD complexes and how RUNX2, p73 and TEAD effectively compete for YAP1 association. Interestingly, YAP1-TEAD complexes, as well as RUNX factors have been known to be important regulators of embryonic development by affecting cell fate. We show that RASSF1A is a novel regulator of stem cell pluripotency by introducing a cross link between the Hippo and Wnt signalling pathways, via TEAD and β-catenin. More specifically, we demonstrate that RASSF1A is a barrier to somatic cell reprogramming by activating differentiation circuits, but its loss results in upregulation of the core stem cell marker network (NANOG, OCT4 and SOX2) in embryonic stem cells and the pre-implantation mouse embryo. In addition, we find that deregulation of the Hippo pathway in the absence of RASSF1A also leads to increased prevalence of stem cell characteristics in cancer and higher proportion of 'cancer stem cells'. This effect is mediated through both YAP and its paralog TAZ. Finally, we show that a second isoform of RASSF1, RASSF1C, the expression of which is maintained in cancers, contributes to cancer stem cell generation through a similar mechanism. This work concentrates on establishing the biology of RASSF1A in normal tissue and answering whether the broad prognostic value in tumours from biologically distinct tissues is due to a fundamental control of stem cell pluripotency.
first_indexed 2024-03-07T07:50:24Z
format Thesis
id oxford-uuid:b4d9f50d-3a2a-4655-ab38-8bc0d45d36b8
institution University of Oxford
language English
last_indexed 2024-03-07T07:50:24Z
publishDate 2014
record_format dspace
spelling oxford-uuid:b4d9f50d-3a2a-4655-ab38-8bc0d45d36b82023-07-04T10:09:47ZRASSF1A regulation of transcription factors in tumourigenesis and stem cell fate determinationThesishttp://purl.org/coar/resource_type/c_db06uuid:b4d9f50d-3a2a-4655-ab38-8bc0d45d36b8Medical SciencesEnglishOxford University Research Archive - Valet2014Papaspyropoulos, AO'Neill, ERASSF1A silencing is the most widely reported epigenetic event in sporadic human malignancies and is increasingly observed to be associated with poorer prognosis and outcome in lung, breast and bladder cancers amongst others. By performing a genetic screen in mice using Sleeping Beauty (SB) transposon-mediated insertional mutagenesis, we identified candidate genes associated with tumourigenesis in the absence of Rassf1a. A top hit in our screen was the terminal differentiation transcription factor Runx2. In this study, we describe how together loss of RASSF1A and RUNX2 exacerbate oncogenic YAP1-TEAD complexes and how RUNX2, p73 and TEAD effectively compete for YAP1 association. Interestingly, YAP1-TEAD complexes, as well as RUNX factors have been known to be important regulators of embryonic development by affecting cell fate. We show that RASSF1A is a novel regulator of stem cell pluripotency by introducing a cross link between the Hippo and Wnt signalling pathways, via TEAD and β-catenin. More specifically, we demonstrate that RASSF1A is a barrier to somatic cell reprogramming by activating differentiation circuits, but its loss results in upregulation of the core stem cell marker network (NANOG, OCT4 and SOX2) in embryonic stem cells and the pre-implantation mouse embryo. In addition, we find that deregulation of the Hippo pathway in the absence of RASSF1A also leads to increased prevalence of stem cell characteristics in cancer and higher proportion of 'cancer stem cells'. This effect is mediated through both YAP and its paralog TAZ. Finally, we show that a second isoform of RASSF1, RASSF1C, the expression of which is maintained in cancers, contributes to cancer stem cell generation through a similar mechanism. This work concentrates on establishing the biology of RASSF1A in normal tissue and answering whether the broad prognostic value in tumours from biologically distinct tissues is due to a fundamental control of stem cell pluripotency.
spellingShingle Medical Sciences
Papaspyropoulos, A
RASSF1A regulation of transcription factors in tumourigenesis and stem cell fate determination
title RASSF1A regulation of transcription factors in tumourigenesis and stem cell fate determination
title_full RASSF1A regulation of transcription factors in tumourigenesis and stem cell fate determination
title_fullStr RASSF1A regulation of transcription factors in tumourigenesis and stem cell fate determination
title_full_unstemmed RASSF1A regulation of transcription factors in tumourigenesis and stem cell fate determination
title_short RASSF1A regulation of transcription factors in tumourigenesis and stem cell fate determination
title_sort rassf1a regulation of transcription factors in tumourigenesis and stem cell fate determination
topic Medical Sciences
work_keys_str_mv AT papaspyropoulosa rassf1aregulationoftranscriptionfactorsintumourigenesisandstemcellfatedetermination